- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Second-line squamous cell oesophageal carcinoma (2L OSCC)
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1454KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 304KB)
Nivolumab – July 2021
Nivolumab: Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
29 October 2021